spacer
home > pmps > winter 2019 > preparing parallel importers for post eu-fmd success
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Preparing Parallel Importers for Post EU-FMD Success

The EU Falsified Medicines Directive (EU-FMD) has been front-of-mind for pharmaceutical companies since the countdown to the legislation began in February 2016. This was when the delegated regulation that set out the details of the safety features requirements was first published. The impact of applying the safety features, particularly the serialisation of every pack, is wide-reaching and affects all parties in the pharma supply chain. One sector which has faced some unique challenges from the legislation is parallel importers (PIs).

The Challenge

Initially, it was observed that the focus of the EU-FMD activity was on manufacturers and their in-house assets. Later, focus shifted to the manufacturers’ extended supply chain participants, such as CMOs and wholesalers. More recently, attention has focussed on the manufacturers’ logistics service providers or third-party logistics.

Something of a ‘scale effect’ has occurred, with the larger manufacturers and their supply chain partners generally implementing first. However, many smaller and medium-sized companies were later to act, and now, in the final rush to compliance before 9 February 2019, many of these companies are still in the process of implementation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ian Haynes is Senior Director at Excellis Europe, specialising in product security, coding, and serialisation. He has an extensive background in the pharma and fine chemical sectors, including technology road-mapping, new product design and introduction, product security coding, serialisation, and engineering projects.
spacer
Ian Haynes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement